Bullish Bayer Highlights Four Future Blockbusters
New Growth Drivers Could Have €12bn Peak Sales
Executive Summary
The German group has shone a light at the J.P. Morgan Healthcare Conference on its new launched drugs Nubeqa and Kerendia, plus its late-stage candidates asundexian and elinzanetant, as it prepares for life after patent expiries on Xarelto and Eylea.
You may also be interested in...
Bayer Expands Kerendia Program In Competitive Heart Failure Space
The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of
Xarelto Declines Are New Normal At Bayer
Sales of the blockbuster Factor Xa blood thinner Xarelto declined more steeply than was expected but Bayer’s second biggest seller Eylea is still performing well.
Bayer May Not Launch In Innovation-Unfriendly European Markets
The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.